Aura Biosciences, Inc.
Financials
Valuation Metrics
Aura Biosciences, Inc.'s Market Cap is $645M. At end of 2025 it was $359M. Ranked #2647 of 3,118 in US market (top 85%), #1135 of 1,474 on NASDAQ (top 77%), #203 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $645M | US#2,647/3,118 Sec#203/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-131M | US—/3,118 Sec—/265 |
| Total Assets | $348M | US#2,876/3,118 Sec#198/265 |
| Net Assets | $315M | US#2,487/3,118 Sec#154/265 |
| Employees | 113 | US#2,588/3,118 Sec#166/265 |
| Value | ||
| P/B | 2.05x | US#1,281/3,118 Sec#61/265 |
| FCF Yield | -15.91% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -41.56% | US#2,630/3,118 Sec#140/265 |
| ROA | -37.63% | US#2,930/3,118 Sec#183/265 |
| Financial Health | ||
| Debt Ratio | 10.42% | US#114/3,118 Sec#52/265 |
| Total Debt | $17M | US#2,764/3,118 Sec#192/265 |
| FCF | $-103M | US#2,635/3,118 Sec#148/265 |
| Cash | $68M | US#2,441/3,118 Sec#205/265 |
| Current Ratio | 16.82x | US#141/3,118 Sec#37/265 |
| Performance | ||
| 1Y Return | 3.31% | US#1,793/3,118 Sec#149/265 |
| 1M Return | 2.46% | US#1,994/3,118 Sec#130/265 |
| From 52W High | -34.59% | US#2,183/3,118 Sec#150/265 |
| 1Y MDD | -32.58% | US#1,479/3,118 Sec#76/265 |
| Trading | ||
| Volume | 640,969 shares | US#2,134/3,118 Sec#207/265 |
| Trading Value | $4M | US#2,806/3,118 Sec#229/265 |
| Per Share | ||
| EPS | $-1.27 | US—/3,118 Sec—/265 |
| BPS | $3.05 | US#2,480/3,118 Sec#160/265 |
Company Info
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.